Movement Alert｜PegBio Intraday Decline 8.04%, Rani Therapeutics Catalyst Fading Amid Broad Biotech Sector Selloff

Market Focus07-17

On July 17, PegBio (02565.HK) fell 8.04% in regular trading, trading at HK$6.27/share, with turnover of HK$47.87 million.

The decline reflects continued profit-taking as the catalytic effect of the company's memorandum of understanding with Nasdaq-listed Rani Therapeutics dissipates. PegBio's stock had surged approximately 29% on July 10 following the announcement of the three-year MoU, under which both parties plan to leverage Rani's proprietary RaniPill oral biologics delivery platform to conduct oral formulation screening and preclinical development for PegBio's obesity and metabolic disease candidates. The collaboration remains in early screening stages with a lengthy path to clinical advancement and commercialization, prompting investors to lock in gains accumulated during the initial rally.

Adding to selling pressure, the broader biotechnology sector traded under significant stress on the same day. Within the sector, AKESO fell 9.77%, 3SBIO declined 9.77%, SKB BIO dropped 4.77%, INNOVENT BIO lost 3.82%, and BEIGENE slid 2.73%, amplifying sector-wide risk-off sentiment and intensifying individual stock outflows.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1148765165?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-17 10:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148765165","market":"hk","top_or_hot":-1,"title":"Movement Alert｜PegBio Intraday Decline 8.04%, Rani Therapeutics Catalyst Fading Amid Broad Biotech Sector Selloff","media":"Market Focus","content":"<p><p>On July 17, PegBio (02565.HK) fell 8.04% in regular trading, trading at HK$6.27/share, with turnover of HK$47.87 million.</p><p>The decline reflects continued profit-taking as the catalytic effect of the company's memorandum of understanding with Nasdaq-listed Rani Therapeutics dissipates. PegBio's stock had surged approximately 29% on July 10 following the announcement of the three-year MoU, under which both parties plan to leverage Rani's proprietary RaniPill oral biologics delivery platform to conduct oral formulation screening and preclinical development for PegBio's obesity and metabolic disease candidates. The collaboration remains in early screening stages with a lengthy path to clinical advancement and commercialization, prompting investors to lock in gains accumulated during the initial rally.</p><p>Adding to selling pressure, the broader biotechnology sector traded under significant stress on the same day. Within the sector, AKESO fell 9.77%, 3SBIO declined 9.77%, SKB BIO dropped 4.77%, INNOVENT BIO lost 3.82%, and BEIGENE slid 2.73%, amplifying sector-wide risk-off sentiment and intensifying individual stock outflows.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜PegBio Intraday Decline 8.04%, Rani Therapeutics Catalyst Fading Amid Broad Biotech Sector Selloff</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜PegBio Intraday Decline 8.04%, Rani Therapeutics Catalyst Fading Amid Broad Biotech Sector Selloff\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-17 10:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 17, PegBio (02565.HK) fell 8.04% in regular trading, trading at HK$6.27/share, with turnover of HK$47.87 million.</p><p>The decline reflects continued profit-taking as the catalytic effect of the company's memorandum of understanding with Nasdaq-listed Rani Therapeutics dissipates. PegBio's stock had surged approximately 29% on July 10 following the announcement of the three-year MoU, under which both parties plan to leverage Rani's proprietary RaniPill oral biologics delivery platform to conduct oral formulation screening and preclinical development for PegBio's obesity and metabolic disease candidates. The collaboration remains in early screening stages with a lengthy path to clinical advancement and commercialization, prompting investors to lock in gains accumulated during the initial rally.</p><p>Adding to selling pressure, the broader biotechnology sector traded under significant stress on the same day. Within the sector, AKESO fell 9.77%, 3SBIO declined 9.77%, SKB BIO dropped 4.77%, INNOVENT BIO lost 3.82%, and BEIGENE slid 2.73%, amplifying sector-wide risk-off sentiment and intensifying individual stock outflows.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02565","symbol_name":"派格生物医药-B","start_time":0,"source_url":"","article_id":"1148765165","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148765165","pubTimestamp":1784254641,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 17, PegBio (02565.HK) fell 8.04% in regular trading, trading at HK$6.27/share, with turnover of HK$47.87 million.The decline reflects continued profit-taking as the catalytic effect of the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02565":"派格生物医药-B"},"translate_title":"走势警报|PegBio盘中下跌8.04%，Rani Therapeutics催化剂在生物技术板块普遍抛售中消退","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02565":1},"content_text":"On July 17, PegBio (02565.HK) fell 8.04% in regular trading, trading at HK$6.27/share, with turnover of HK$47.87 million.The decline reflects continued profit-taking as the catalytic effect of the company's memorandum of understanding with Nasdaq-listed Rani Therapeutics dissipates. PegBio's stock had surged approximately 29% on July 10 following the announcement of the three-year MoU, under which both parties plan to leverage Rani's proprietary RaniPill oral biologics delivery platform to conduct oral formulation screening and preclinical development for PegBio's obesity and metabolic disease candidates. The collaboration remains in early screening stages with a lengthy path to clinical advancement and commercialization, prompting investors to lock in gains accumulated during the initial rally.Adding to selling pressure, the broader biotechnology sector traded under significant stress on the same day. Within the sector, AKESO fell 9.77%, 3SBIO declined 9.77%, SKB BIO dropped 4.77%, INNOVENT BIO lost 3.82%, and BEIGENE slid 2.73%, amplifying sector-wide risk-off sentiment and intensifying individual stock outflows.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.0","shortVersion":"4.47.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1148765165","isCrawlerRequest":true}